• Tate & Lyle's half-year adjusted EBITDA fell 8% to £197 million on lower pricing, capability investments and cost inflation.
• Revenue rose to £1.04 billion, while adjusted free cash flow increased to £100 million for the six months ended September 30, 2026.
• Ingredion's acquisition remains subject to regulatory approvals, with completion expected in the second half of calendar 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tate & Lyle plc published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.